Nice to see a well written article on AGA in a high profile journal like Nature Biotechnology.
There isn't actually too much information on the second page (the article only consists of 2 pages). However, there is mentioning of another Milan-based company developing a topical DHT antagonist which sounds to have potentials:
"The oral DHT inhibitor Propecia, also used in a higher dose for treating enlarged prostates, slows hair loss but has potential side effects that include impotence and dizziness. Moreover, the drug is approved only for men, since exposures during pregnancy can harm the fetus.
Instead, Cassiopea of Milan, Italy is developing a topical DHT antagonist called Breezula for alopecia treatment. According to the company’s chief executive officer, Diana Harbort, the drug breaks down into harmless byproducts on entering circulation. If approved, Breezula would be the first anti-DHT compound available for use in both men and women. Currently a boutique firm specializing in dermatology, Cassiopeia was spun off by its parent company, Cosmo Pharmaceuticals, in January 2015."
There isn't actually too much information on the second page (the article only consists of 2 pages). However, there is mentioning of another Milan-based company developing a topical DHT antagonist which sounds to have potentials:
"The oral DHT inhibitor Propecia, also used in a higher dose for treating enlarged prostates, slows hair loss but has potential side effects that include impotence and dizziness. Moreover, the drug is approved only for men, since exposures during pregnancy can harm the fetus.
Instead, Cassiopea of Milan, Italy is developing a topical DHT antagonist called Breezula for alopecia treatment. According to the company’s chief executive officer, Diana Harbort, the drug breaks down into harmless byproducts on entering circulation. If approved, Breezula would be the first anti-DHT compound available for use in both men and women. Currently a boutique firm specializing in dermatology, Cassiopeia was spun off by its parent company, Cosmo Pharmaceuticals, in January 2015."
Comment